The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Significantly improving HRQL and neurocognition in high-risk sickle cell following familial ASCT
Mitchell Cairo, MD, of New York Medical College, Valhalla, NY, discusses the NYMC-571 trial (NCT02675959). This showed significantly improved long-term health-related quality of life and neurocognition in high-risk sickle cell disease patients following familial haploidentical stem cell transplantation that used CD34-enriched and CD3 mononuclear addback. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
